Multicenter Validation of a Risk Prediction Model for MDRGNB Infection (PRIOR)
Prospective Validation of a Risk Prediction Model for MDRGNB Infection: A Multicenter Real-World Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Dayu Chen, Pharmacist in Charge, PharmD
- Phone Number: +86-025-83106666-60924
- Email: cdy_pharmacy@njglyy.com
Study Contact Backup
- Name: Juan He, Professor, PharmD
- Email: hejuanwin@126.com
Study Locations
-
-
-
Ankang, China
- Not yet recruiting
- Ankang People's Hospital
-
Contact:
- Zhiying Gao, Pharmacist in Charge
- Phone Number: +86-0915-3368788
- Email: 18704630749@163.com
-
Principal Investigator:
- Zhiying Gao
-
Datong, China
- Not yet recruiting
- Sinopharm Tongmei General Hospital
-
Contact:
- Xiaomin Feng, Associate Professor
- Phone Number: +86-0352-7028190
- Email: Fxm10010@163.com
-
Principal Investigator:
- Xiaomin Feng
-
Ganzhou, China
- Not yet recruiting
- First Affiliated Hospital of Gannan Medical University
-
Contact:
- Peipei Liu, Pharmacist in Charge, PharmD
- Phone Number: +86-0797-8266000
- Email: liupei0322@163.com
-
Principal Investigator:
- Peipei Liu
-
Hangzhou, China
- Not yet recruiting
- Zhejiang Provincial People's Hospital
-
Contact:
- Xiaoyuan Chen, Associate Professor, PhD
- Phone Number: +86-0571-87666666
- Email: chenxiaoyuan@hmc.edu.cn
-
Principal Investigator:
- Xiaoyuan Chen
-
Hangzhou, China
- Recruiting
- Zhejiang Hospital
-
Contact:
- Zhouye Song, Pharmacist in Charge
- Phone Number: +86-0571-87987373
- Email: szy1066@126.com
-
Principal Investigator:
- Zhouye Song
-
Huaian, China
- Not yet recruiting
- Huaian First People's Hospital
-
Contact:
- Yu Du
- Phone Number: 0517-84907287
- Email: 1204624315@qq.com
-
Principal Investigator:
- Yu Du
-
Nanning, China
- Recruiting
- Guangxi Provincial Tumor Hospital
-
Contact:
- Linyu Wang, Pharmacist in Charge
- Phone Number: +86-0771-5331955
- Email: 1044548733@qq.com
-
Principal Investigator:
- Linyu Wang
-
Shanghai, China
- Recruiting
- Shanghai Ruijin Hospital
-
Contact:
- Juan He, Professor, PharmD
- Phone Number: +86-021-64370045
- Email: hejuanwin@126.com
-
Principal Investigator:
- Juan He
-
Xi'an, China
- Not yet recruiting
- Shaanxi Provincial People's Hospital
-
Contact:
- Lu Cao, Associate Professor
- Phone Number: +86-029-85251331
- Email: caolu_cpu@163.com
-
Principal Investigator:
- Lu Cao
-
Zhanjiang, China
- Not yet recruiting
- Zhanjiang Central People's Hospital
-
Contact:
- Xi Cao, Pharmacist in Charge
- Phone Number: +86-0759-3157999
- Email: nkyy_cx@126.com
-
Principal Investigator:
- Xi Cao
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital
-
Contact:
- Dayu Chen, Pharmacist in Charge, PharmD
- Phone Number: +86-025-83106666-60924
- Email: cdy_pharmacy@njglyy.com
-
Sub-Investigator:
- Yao Du, MPharm
-
Principal Investigator:
- Dayu Chen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years;
- ICU stay ≥48 hours;
- At least one clinical microbiological specimen collected and submitted for testing within 48 hours of ICU admission, with the first submission time designated as the index time;
- Core predictive variables of the model extractable from electronic medical records or laboratory information systems.
Exclusion Criteria:
- For patients with multiple ICU admissions, only the first ICU stay was retained;
- Missing or indeterminate primary outcome;
- Missing key predictive variables that could not be handled according to prespecified rules.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Observation group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MDRGNB infection
Time Frame: 48 hours after ICU admission
|
The objective of this study was to observe whether enrolled patients developed early MDRGNB infection and to validate the model's performance.
The occurrence of MDRGNB infection was adjudicated by integrating clinical manifestations with culture results from collected specimens.Baseline and model variables: Collected within 48 hours of ICU admission.Primary outcome: Determined based on the results of the first submitted specimen.
|
48 hours after ICU admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
28-day mortality
Time Frame: 28 day after ICU admission
|
28-day mortality
|
28 day after ICU admission
|
|
Adverse events related to antibiotic within 28 days
Time Frame: 28 day after admission
|
Adverse events related to antibiotic within 28 days, defined by Naranjo scale.
|
28 day after admission
|
|
Sequential Organ Failure Assessment (SOFA) score at 48 hours
Time Frame: 48 hours after ICU admission
|
SOFA score at 48 hours, higher SOFA score mean a worse outcome
|
48 hours after ICU admission
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-0453-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.